Cullen Frost Bankers Inc. Reduces Position in Eli Lilly And Co (LLY)

Cullen Frost Bankers Inc. lessened its stake in Eli Lilly And Co (NYSE:LLY) by 6.1% in the 3rd quarter, Holdings Channel reports. The firm owned 23,631 shares of the company’s stock after selling 1,524 shares during the period. Cullen Frost Bankers Inc.’s holdings in Eli Lilly And Co were worth $2,536,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in Eli Lilly And Co by 1.3% in the 2nd quarter. BlackRock Inc. now owns 66,644,897 shares of the company’s stock valued at $5,686,808,000 after purchasing an additional 864,451 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Eli Lilly And Co by 7.5% in the 2nd quarter. Janus Henderson Group PLC now owns 10,008,768 shares of the company’s stock valued at $854,049,000 after purchasing an additional 700,582 shares during the last quarter. Morgan Stanley increased its holdings in Eli Lilly And Co by 37.8% in the 2nd quarter. Morgan Stanley now owns 4,473,537 shares of the company’s stock valued at $381,727,000 after purchasing an additional 1,227,888 shares during the last quarter. Bank of Montreal Can increased its holdings in Eli Lilly And Co by 4.6% in the 3rd quarter. Bank of Montreal Can now owns 4,330,654 shares of the company’s stock valued at $464,722,000 after purchasing an additional 191,374 shares during the last quarter. Finally, Swiss National Bank increased its holdings in Eli Lilly And Co by 2.3% in the 2nd quarter. Swiss National Bank now owns 3,851,143 shares of the company’s stock valued at $328,618,000 after purchasing an additional 84,800 shares during the last quarter. Hedge funds and other institutional investors own 76.36% of the company’s stock.

Several analysts recently weighed in on LLY shares. BMO Capital Markets lifted their target price on shares of Eli Lilly And Co from $78.00 to $80.00 and gave the company a “$89.43” rating in a report on Thursday, July 19th. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a report on Wednesday, July 18th. Cantor Fitzgerald set a $100.00 price target on shares of Eli Lilly And Co and gave the company a “buy” rating in a research report on Tuesday, July 17th. Jefferies Financial Group set a $100.00 price target on shares of Eli Lilly And Co and gave the company a “buy” rating in a research report on Sunday, July 15th. Finally, Cowen set a $105.00 price target on shares of Eli Lilly And Co and gave the company a “buy” rating in a research report on Tuesday, July 24th. Seven investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $111.53.



In other news, major shareholder Eli & Co Lilly sold 4,531 shares of Eli Lilly And Co stock in a transaction on Monday, August 13th. The shares were sold at an average price of $14.33, for a total transaction of $64,929.23. Following the completion of the sale, the insider now directly owns 3,934,137 shares of the company’s stock, valued at approximately $56,376,183.21. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 195,000 shares of Eli Lilly And Co stock in a transaction on Monday, August 6th. The stock was sold at an average price of $102.15, for a total transaction of $19,919,250.00. Following the sale, the insider now directly owns 120,735,804 shares of the company’s stock, valued at $12,333,162,378.60. The disclosure for this sale can be found here. Insiders sold a total of 1,380,271 shares of company stock valued at $143,763,002 in the last three months. 0.11% of the stock is currently owned by corporate insiders.

Shares of LLY stock opened at $108.44 on Thursday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.40 and a quick ratio of 1.09. Eli Lilly And Co has a 52 week low of $73.69 and a 52 week high of $116.61. The company has a market capitalization of $114.26 billion, a price-to-earnings ratio of 25.34, a price-to-earnings-growth ratio of 1.74 and a beta of 0.29.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be given a $0.5625 dividend. The ex-dividend date is Wednesday, November 14th. This represents a $2.25 annualized dividend and a yield of 2.07%. Eli Lilly And Co’s dividend payout ratio is presently 52.57%.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: How is a Moving Average Calculated?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply